Seres Therapeutics, Inc (MCRB) insider trading

Every open-market stock purchase and sale by Seres Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • Insiders sold $52.7K over the last 12 months (12 sales). No open-market buys.
  • Last insider buy: Nutritional Health LTP Fund General Partner LLC (10% owner), $18.4M, 4 years ago.

Last 12 months: insiders bought $0 (0 buys) and sold $52.7K (12 sales). Last close $6.63 on Jun 4, 2026.

Recent MCRB insider trades

DateInsiderTradeValue
May 18, 2026Eric D. Shaff (Insider)Sold$2K
May 18, 2026Thomas DesRosier (Insider)Sold$595
May 18, 2026Matthew R Henn (Insider)Sold$580
May 18, 2026Kelly Brady (Insider)Sold$444
May 15, 2026Matthew R Henn (Insider)Bought (not open market)—
May 15, 2026Kelly Brady (Insider)Bought (not open market)—
May 15, 2026Thomas DesRosier (Insider)Bought (not open market)—
May 15, 2026Thomas DesRosier (Insider)Bought (not open market)—
May 15, 2026Eric D. Shaff (Insider)Bought (not open market)—
May 15, 2026Eric D. Shaff (Insider)Bought (not open market)—
May 15, 2026Eric D. Shaff (Insider)Bought (not open market)—
May 15, 2026Thomas DesRosier (Insider)Bought (not open market)—
May 15, 2026Kelly Brady (Insider)Bought (not open market)—
May 15, 2026Kelly Brady (Insider)Bought (not open market)—
May 15, 2026Matthew R Henn (Insider)Bought (not open market)—
May 15, 2026Matthew R Henn (Insider)Bought (not open market)—
Mar 4, 2026Kelly Brady (Insider)Bought (not open market)—
Mar 4, 2026Thomas DesRosier (Insider)Bought (not open market)—
Mar 4, 2026Matthew R Henn (Insider)Bought (not open market)—
Mar 4, 2026Marella Thorell (Insider)Bought (not open market)—
Mar 4, 2026Richard N Kender (Insider)Bought (not open market)—
Feb 15, 2026Eric D. Shaff (Insider)Sold$2.2K
Feb 15, 2026Matthew R Henn (Insider)Sold$754
Feb 15, 2026Thomas DesRosier (Insider)Sold$661
Feb 15, 2026Teresa L. Young (Insider)Sold$635

Who's trading MCRB

Get free alerts when an insider at Seres Therapeutics, Inc files a new trade →